

**Brandes Investment Partners**  
**Global Equity Strategy Notes**  
**Third Quarter 2025 (July 1 – September 30, 2025)**

The Brandes Global Equity Strategy rose 4.98% net of fees and 5.05% gross of fees, underperforming its benchmark, the MSCI World Index, which increased 7.27%, and outperforming the MSCI World Value Index, which grew by 5.83%.

<b>Annualized total return as of September 30, 2025</b>	<b>1-year</b>	<b>5-year</b>	<b>10-year</b>
Brandes Global Equity Composite (net)	15.77%	15.65%	9.51%
Brandes Global Equity Composite (gross)	16.38%	16.47%	10.65%
MSCI World Index	17.25%	14.40%	12.42%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

**Positive Contributors**

Leading contributors included several holdings in the consumer discretionary and financials sectors.

Within the consumer discretionary sector, China-based Alibaba and France-based Kering performed well. Alibaba rallied on aggressive artificial intelligence (AI) investment plans, continued significant AI-related product and cloud revenue growth, and recovery in Chinese consumer spending—all of these drivers boosted Alibaba's core e-commerce platforms. We believe that our long-term investment case continues to be validated by Alibaba's dominant market position in e-commerce and cloud services, combined with its strong balance sheet.

Kering rose due to the anticipated turnaround efforts led by incoming CEO Luca de Meo, combined with promising signs for the core Gucci brand under new creative leadership. In our view, the company continues to have upside potential as management focuses on brand equity, cost cutting and financial discipline which could position it well for margin recovery and long-term growth. U.S. flooring company, Mohawk, also saw its fortunes rise, buoyed by resilient demand in the U.S. housing market, as well as through cost discipline.

Financials continued to be one of the best-performing sectors as several investments delivered positive results. Switzerland-based UBS continued to gain from integration synergies following its Credit Suisse acquisition, while Austria-based Erste Group's Eastern European footprint delivered strong net interest income growth. U.S.-based Citigroup's restructuring efforts and focus on its core banking business and operating efficiency resulted in improved investor sentiment. The sector's strength was underpinned by a favorable interest rate environment globally, supporting improved net interest margins.

While our underweight to technology-related companies was a detractor, several that we owned performed well, including semiconductor producers Korea-based Samsung and U.S.-based Micron Technology, as well as Taiwan-based data center company Wiwynn. Wiwynn's exposure to hyperscale data centers and AI infrastructure positioned it well amid rising demand for high-performance computing. Samsung and Micron experienced solid successes in their memory businesses, reinforced by increasing demand for AI applications.

**Performance Detractors**

The largest detractors were several companies domiciled in France. Although they are all globally oriented companies, due to rising political uncertainty, the French stock market underperformed. Included in this group is our recent purchase, Capgemini. It fell due to concerns about the impact of AI on the information technology (IT) services industry, as well as policy uncertainty in the U.S. regarding immigrant visas, which are commonly relied on in the IT services industry. However, we believe Capgemini is well positioned to benefit from a recovery in its European industrial end-markets and has the potential to benefit from increased IT service spending for the deployment of enterprise AI applications. Two other IT service organizations, Amdocs and Cognizant (both U.S.-based), also declined.

Other detractors included France-based pharmaceutical firm Sanofi and advertising agency Publicis. Health care was again one of the weaker performing sectors as ambiguities in the policy environment continued to depress share prices. Others that diminished returns included U.S.-based Cigna and Cardinal Health. Despite the challenges they faced, our business case for retaining these investments remains centered on the indispensable need for health care and what we foresee as likely long-term demand growth from an aging population.

Payments company Fiserv and media company Comcast also created a drag on results. Fiserv saw its shares soften as the market expressed concern about slowing growth in its merchant acceptance business. Though near-term sentiment for the company has somewhat soured, our long-term investment thesis remains intact and is supported by Fiserv's scale and recurring revenue base.

As already noted, our underweight to the U.S. in general and to U.S. technology-related companies specifically dampened returns as the technology sector continued its strong rebound after beginning the year on a low note.

### **Select Activity in the Quarter**

The investment committee initiated new positions in U.S.-based health care service company UnitedHealth Group and Ireland-based contract research organization ICON, as well as IT service company EPAM. Several holdings rose in value; we sold those in U.S.-based BNY Mellon and U.K.-based Rolls Royce when they reached our estimates of their respective intrinsic value.

Founded in 1977, UnitedHealth is the largest health insurer in the United States. The company is a major consolidator of health plans, care providers and other services that underlie the health care sector, making it a leading player in vertical integration, diversification and scale.

UnitedHealth has recently faced several challenges. These include a cybersecurity attack, the homicide of its insurance business CEO, a series of *Wall Street Journal* articles investigating the company's Medicare billing practices, and potential antitrust concerns. As market negativity toward UnitedHealth has risen, its valuation has fallen to what we believe is an attractive level. In our view, growth in health-care spending should continue to outpace overall economic growth due to an aging U.S. population. We believe that UnitedHealth is well positioned to capitalize on this trend given its scale and integrated value chain.

ICON is a leading global clinical research organization (CRO), offering a full suite of services for the pharmaceutical industry across the clinical development cycle, including trial design, execution, post-market commercialization and data solutions. Following its acquisition of PRA Health in 2021, ICON became the largest pure-play CRO, with 16% share of the global clinical outsourcing market. The company boasts a vast clinical site network that allows fast patient recruitment.

ICON has been out of favor as the CRO industry faces slowing growth due to already high outsourcing penetration and cyclical headwinds from reduced biotech funding. However, we believe ICON is well equipped to navigate these challenges given its healthy balance sheet and solid competitive positioning. Additionally, with deleveraging from the PRA acquisition now complete, ICON can utilize its capital to fund future growth (e.g., by consolidating weaker players) and share buybacks, in our opinion. With ICON stock trading at less than 11x price/earnings when we initiated our position, we see it as an attractive value opportunity. Our investment case centers on ICON's leadership in clinical trial services, strong backlog growth and margin expansion potential. We think the company is well positioned to benefit from increased outsourcing by pharmaceutical firms and that it has demonstrated consistent execution across its global footprint.

Our full sale of Rolls-Royce marked the conclusion of an investment that began in May 2022. When purchased, the company was trading at a sizable discount to our estimate of its intrinsic value following a period of severe disruption caused by COVID-19. Our thesis centered on Rolls-Royce's dominant position in the widebody aircraft engine market, its high-margin aftermarket services business, and its exposure to long-term secular growth in global air travel.

During our holding period, we made several upward adjustments to our estimate of Rolls-Royce's intrinsic value as the company made substantial progress in strengthening its balance sheet, improving operational execution and restoring

profitability. By mid-2025, the stock had appreciated robustly, supported by a rebound in civil aerospace volumes, margin expansion and a return to investment-grade credit metrics.

With Rolls-Royce stock climbing to our revised intrinsic value estimate, we sold our shares. While we continue to view the company as a high-quality industrial franchise, we believe the risk/reward profile has become less compelling versus other opportunities in the portfolio.

### ***Year-to-Date Briefing***

For the nine months ended September 30, 2025, the Brandes Global Equity Strategy returned 24.40% net of fees and 24.70% gross of fees, surpassing the MSCI World Index, which returned 17.43%, and the MSCI World Value Index, which was up 16.89%.

The outperformance of international stocks (MSCI EAFE vs. MSCI USA) has been a tailwind for the strategy, given our value exposure and overweight to international stocks. However, most of our outperformance has been generated by stock selection. A variety have driven results, led by Germany-based construction materials company Heidelberg Materials, aerospace companies Rolls-Royce and Embraer, as well as Erste Group Bank. Other contributors include several emerging market companies and holdings that have benefitted from helping supply the AI buildout, such as technology company Wiwynn, Alibaba, and memory manufacturer Micron.

These investments reflect the strategy's strength in the technology and financials sectors, two of the best-performing sectors in the benchmark this year. While health care and consumer staples have lagged the benchmark, our investments in them have done better and aided relative outcomes; contributors include Imperial Brands, as well as CVS, UnitedHealth and McKesson.

Top detractors mostly align with those for the quarter. Led by payments company Fiserv, they include communication services firms U.K.-based advertising agency WPP and U.S.-based Comcast, as well as France-based Publicis. IT services companies Cognizant, Capgemini and Amdocs also reduced returns as they were down slightly in an up market.

### ***Current Positioning***

The Brandes Global Equity Strategy holds overweights in the economically sensitive financials sector and the more defensive health care and consumer staples sectors, while maintaining its largest sector underweight to technology. As financials have performed well during the past year, we have pared some of our exposure, and our overweight relative to the benchmark has decreased.

Geographically, we hold overweight positions in the United Kingdom, France and emerging markets, while remaining underweight in the United States and Japan. During the past quarter, our weight to the U.K. decreased as several companies performed well and we pared or sold some of our allocation. Meanwhile, recent buys elevated our U.S. weight, though it was still materially below the massive index weight at quarter end. We believe the differences between the strategy and the MSCI World Index make it an excellent complement and diversifier to passive and growth-oriented strategies.

While U.S. markets slightly topped international markets (MSCI USA vs. MSCI EAFE) for the quarter, international developed (MSCI EAFE) and emerging markets (MSCI EM) remain significantly ahead of the U.S. on a year-to-date basis. Typically, these cycles between International and U.S. markets lasted for several years. Given where valuations are today relative to U.S. stocks, we believe that international stocks are well primed for the future on a go-forward basis.

Global value stocks continue to trade within the least expensive quartile relative to growth (MSCI World Value vs. MSCI World Growth) since the style indices began. This is evident across various valuation measures, including price/earnings, price/cash flow and enterprise value/sales. Historically, such discount levels often signaled attractive subsequent relative returns for value stocks during the next three- to five-year-plus period. This is encouraging because our strategy, guided by our value philosophy and process, has had the tendency to do better than the value index when that index exceeded the broad benchmark.

Looking ahead, we are excited about the long-term prospects of companies held by the strategy, which in aggregate traded at more compelling valuation levels than the benchmark, in our opinion.

For term definitions, please refer to <https://www.brandes.com/termdefinitions>.

For index definitions, please refer to <https://www.brandes.com/benchmark-definitions>.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

Diversification does not assure a profit or protect against a loss in a declining market.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**United States:** Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

**Singapore/Asia:** FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

**Canada:** FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.